Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$3.50
-$0.25(-2.12%)
At close: 4:00 PM EST
$3.50
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.40 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$183.71M
Enterprise Value$101.44
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$35.34M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 10, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding47,105,980
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside14.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.29
Revenue Forecast (FY)$169.86M
Bulls Say, Bears Say
Bulls Say
Installed Base & Consumables Pull-throughA >2,300 instrument installed base supports a durable razor-and-blades revenue stream: instruments drive recurring, high-margin consumables and services. This installed footprint creates customer stickiness, predictable repeat revenue, and a structural advantage versus new entrants over the next 2–6 months and beyond.
High Non‑GAAP Gross MarginsSustained non‑GAAP gross margins near 50% indicate favourable unit economics for assays and consumables. High gross margins support margin resilience as revenue scales, provide room to absorb investments in commercial/diagnostics, and materially underpins the path to adjusted profitability over coming quarters if top-line stabilizes.
Healthy Cash Position; Low LeverageA cash balance above $100M combined with minimal debt gives the company runway to execute commercialization, diagnostics development and integration plans without immediate financing. Low leverage reduces solvency risk and supports strategic flexibility while management targets H2 2026 cash‑flow breakeven.
Bears Say
Persistent Cash BurnLarge, recurring negative operating and free cash flows signal ongoing cash burn that erodes equity and increases reliance on external funding if losses persist. Even with improving adjusted metrics, negative cash flows constrain capital allocation, limit optionality, and heighten execution risk over the next several quarters.
Material Organic Revenue DeclinesSharp organic declines in core Simoa and spatial product lines reflect weakening end‑market demand (academic and pharma). Reduced organic demand undermines recurring consumables pull‑through, lengthens payback on instrument placements, and raises the risk that topline growth will remain dependent on acquisitions or partners rather than organic recovery.
Soft Instrument PlacementsWeak instrument revenue and delayed placements limit expansion of the installed base, directly reducing future consumables consumption and recurring revenue growth. Slower placements compress the long‑term revenue cadence of the razor‑and‑blades model and make margin improvements harder to sustain absent instrument momentum.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.40 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $183.71M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Aug 10, 2026 which is in 18 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on May 06, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.143.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.41.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,105,980 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went down -16.413%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (14.29% Upside)
$4.00 (14.29% Upside)
Hedge Fund Trend
Increased
By 768.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.53%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(14.29% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
6.89% Insiders
19.65% Mutual Funds
1.24% Other Institutional Investors
62.01% Public Companies and
Individual Investors